Elena-Bianca Barbir, MD
@delphile
Transplant and onco-nephrologist @UAlbertaNeph. @MayoClinic, @UBC and @Queensu alum. Runner. Salt Water Person.
You might like
Dr Phil Halloran at CST on what the molecular microscope has taught us so far about kidney allograft rejection - “rejection is a chronic condition not an episode”.
CAR-T therapy and Lymph node architecture Amazing lecture by @BradRovin on Lupus Nephritis #GlomConHawaii
We are honored to welcome 🤗 Dr Pierre Ronco as Visiting Professor at @MayoClinicNeph #MedEd Grand Rounds tilted “New advances in immune-mediated podocytopathies: Is anti-nephrin the new anti-PLA2R?” 👩🔬 Key Conclusions •🧪 Anti-nephrin antibodies confirmed as correlating with…
🚨 Editor’s Choice 🚨 "The impact of the Banff v-lesion on rejection classification and outcomes: Insights from a multicenter study," by Wellekens et al. amjtransplant.org/article/S1600-…
I really enjoyed this year’s ASON symposium. Learned lots, reconnected with friends and mentors, and made new friends. Grateful to @HerrmannMd, Dr Nelson Leung, and @LeticiaRolonMD for the invitation. Looking forward to next year’s symposium already! 🥂
Final picture! We would like to thank all the Speakers and Moderators and everyone who attended in person and livestream ! Safe travels back home . @rc_oncneph @LeticiaRolonMD @onconeph @AbdullahJalalMD @MayoClinicNeph @onconephsociety
👀 Check out our September Literature Watch, "Location, location, location—How real estate immunity and preservation of self are defined" by Drinkwater et al: amjtransplant.org/article/S1600-…
Membranous nephropathy has undergone a paradigm shift due to the discovery of unique MN antigens. MN has gone from idiopathic to ➡️ primary vs. secondary ➡️ where an antigen can be detected in ~80% of MN. This is a comprehensive review of each antigen. nature.com/articles/s4158…
1/5 SPLENOMEGALY/HYPERSPLENISM Mechanisms of splenomegaly: • Congestive • Work hypertrophy • Infiltrative What enlarges? • Red pulp: macrophages, sinusoids, blood • White pulp: lymphocytes, plasma cells • Infiltrative: tumor, storage cells, granulomas, amyloid #MedEd
Important new arguments for the discussion, which B cell-targeting therapy to involve in the treatment of autoimmune diseases. May be even more important in alloimmunity? ard.eular.org/article/S0003-…
Not all drug related TMA’s are made equal. But for a subset (I.e. VEGFi, Gemcitabine), terminal complement blockade allows continuation of the offending drug, with important implications for progression free survival in the long term.
Complement Inhibition Enables Anti-VEGF Receptor Therapy in Renal-Limited TMA. More options to keep patients on life-saving therapy. Check it out.👇🏽@ISNeducation @delphile @KIReports @AbdullahJalalMD @MayoClinicNeph kireports.org/article/S2468-…
Excited to share our experience using complement inhibition for re-challenging and maintaining anti-VEGF therapy in renal limited TMA. A valuable strategy to keep patients on life-saving treatment #onconephrology @HerrmannMd @delphile @KIReports @onconephsociety @MayoClinicNeph…
Baffling: PGNMID, monoclonal no more I got this consult case as immune complex-MPGN LM- MPGN pattern IF- IgG, C3, C1q, kappa & lambda 3+ Did IgG subtypes-IgG3 3+, all others negative EM- mottled deposits Dx- Proliferative GN, IgG3, but ? with monoclonal IgG deposits (PGNMID)
Don't miss this @MayoClinicNeph conference! Onco-Nephrology Symposium will cover nephrotoxicity of chemotherapeutic agents, patients with dialysis-dependent end-stage renal disease, & much more. Register for Sept. 11-12 in Minnesota & via livestream. ce.mayo.edu/nephrology/con…
IgM Variant of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits: A Case Series bit.ly/3Ec18Od #OpenAccess @Bhanu2405 @SethiRenalPath #VisualAbstract
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. ja.ma/45mitxx
💡New resources- Management recommendations for kidney transplantation in patients with plasma cell dyscrasia. Useful info on pre-tx eval, post-tx monitoring of recurrence, immunosuppression mgmt. @Kidney_Int @AST_KPCOP w IKMG. More info 👇. kidney-international.org/article/S0085-…
Another major milestone for our C3G patients & community!! C3 inhibitor, Pegcetacoplan approved for C3G and IC-MPGN 🧬💊 investors.apellis.com/news-releases/… #C3G #Nephrology #RareDisease #FDAApproval #ComplementTherapy
Organ transplantation saves lives. Yet, according to WHO, only 10% of the global need for transplants is being met. In our latest issue, a Comment introduces the @ESOTtransplant–Lancet Commission on Transplantation. ➡️ hubs.li/Q03yStP20
I am excited to share our latest paper on the potential association between monoclonal gammopathy and ANCA negative vasculitis. Monoclonal testing should be considered in ANCA negative patients. @mvargas07 @fervenzafernan1 journals.lww.com/kidney360/abst…
United States Trends
- 1. Sunderland 94.8K posts
- 2. Jeremiah Smith 1,533 posts
- 3. St. John 5,588 posts
- 4. Arsenal 177K posts
- 5. Texas Tech 9,730 posts
- 6. Philon N/A
- 7. Trossard 9,217 posts
- 8. #GoDawgs 3,430 posts
- 9. #iufb 1,254 posts
- 10. Carnell Tate N/A
- 11. #SUNARS 8,167 posts
- 12. Mendoza 8,004 posts
- 13. Saka 32.6K posts
- 14. Merino 10.4K posts
- 15. Obamacare 176K posts
- 16. Mississippi State 3,912 posts
- 17. Nate Frazier N/A
- 18. Ryan Graves N/A
- 19. Lebby N/A
- 20. Shapen N/A
You might like
Something went wrong.
Something went wrong.